Maryland, D.C., and Virginia — one of the largest life science corridors in the U.S.
Explore →
Philadelphia, South Jersey, and Delaware — a powerhouse of pharma and biotech innovation.
Explore →
North Carolina's Research Triangle — a growing hub for biotech and life sciences.
Explore →
Xcellon Biologics, a Maryland CRDMO specializing in bioconjugates and complex biologics, has signed a definitive agreement to acquire the GMP biologics manufacturing facility built by NextCure, Inc. in Beltsville. The deal gives Xcellon its first cGMP capacity, completes the company’s transition from a development-stage CDMO into an end-to-end CRDMO, and puts a commissioned domestic bioconjugation […]
Read More →University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has received $40 million from the OpenAI Foundation — the nonprofit parent organization that governs the for-profit OpenAI Group PBC — to generate data aimed at making personalized cancer vaccines more effective, the Chapel Hill, North Carolina-based cancer center announced September 15, 2026. Immunologist Benjamin Vincent, […]
Claritev has appointed Ben Letham to its Board of Directors, effective September 14, 2026. “Claritev is fortunate to add a visionary of Ben’s stature to our Board. Over the past two years, we have transformed our leadership, Board, and solution strategy to position Claritev for its next phase of growth,” said Travis Dalton, CEO and […]
Georgiamune, a Gaithersburg, Maryland-based clinical-stage biotech with roughly 30 employees, has raised approximately $92.69 million in Series B financing to advance its cancer and autoimmune disease programs, with Prevail Private Capital and Mubadala Capital leading the round. A Large Round, Structured in Two Tranches The Series B was structured across B1 and B2 tranches and […]
Autolus Therapeutics plc, the commercial-stage biopharmaceutical company with dual headquarters in London and Gaithersburg, Maryland, announced on September 9, 2026 that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to obecabtagene autoleucel (obe-cel) for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Chief Development Officer Dr. Matthias Will said: “SLE and LN are serious […]
Slate Medicines has appointed Kenneth Koblan, PhD, as Chief Scientific Officer as the company advances its migraine pipeline. “Ken’s ability to bridge discovery innovation and development excellence across multiple successful products and novel platforms demonstrates his deep understanding of what it takes to build and advance a world-class pipeline,” said CEO Gregory Oakes. About Kenneth […]
RedHill Biopharma Ltd., the specialty biopharmaceutical company with a U.S. commercial office in Raleigh, North Carolina, announced on September 1, 2026 that it acquired exclusive global and U.S. commercialization rights to Ferring Pharmaceuticals’ Rebyota® and Clenpiq® for a $12 million upfront payment, plus tiered royalties on net sales and potential milestone payments. CEO Dror Ben-Asher […]
Veranex, a Raleigh, North Carolina-based Innovation CRO with more than 800 specialists globally, announced on September 14, 2026 the launch of EFS Explorer alongside the Medical Device Innovation Consortium (MDIC), a new online platform designed to help medtech sponsors identify and evaluate clinical research sites for Early Feasibility Studies (EFS). Pablo Morales, Chief Medical Officer […]
Endpoint Clinical L.P., a Raleigh, North Carolina-based global leader in randomization and trial supply management (RTSM) solutions and a portfolio company of Arsenal Capital Partners, announced on September 14, 2026 that it acquired Bluefin, a Boston-based provider of clinical supply forecasting and planning technology. CEO Nagaraja “Sri” Srivatsan framed the deal around where the industry […]
Remedy Plan Therapeutics, a Gaithersburg, Maryland-based clinical-stage biotech, announced multiple development and corporate milestones on September 15, 2026 for RPT1G, its first-in-class hyperbolic NAMPT inhibitor: patients in Cohort 1 of its Phase 1 trial completed a full 28-day treatment cycle, Cohort 2 enrollment has begun, and the FDA has accepted an IND application to study […]
